offline
AbbVie (ABBV) Surpasses Q1 Earnings and Revenue Estimates
Zacks Equity Research
AbbVie (ABBV) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $2.42 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 6.50%. A quarter ago, it was expected that this drugmaker would post earnings of $2.85 per share when it actually produced earnings of $2.92, delivering a surprise of 2.46%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.01 billion for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 0.51%. This compares to year-ago revenues of $8.62 billion.
...
https://finance.yahoo.com/news/abbvie-ab...01378.html
![[Bild: ABBVd074346591i.png]](https://finviz.com/publish/050421/ABBVd074346591i.png)
Zacks Equity Research
AbbVie (ABBV) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $2.42 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 6.50%. A quarter ago, it was expected that this drugmaker would post earnings of $2.85 per share when it actually produced earnings of $2.92, delivering a surprise of 2.46%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.01 billion for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 0.51%. This compares to year-ago revenues of $8.62 billion.
...
https://finance.yahoo.com/news/abbvie-ab...01378.html
__________________
